Crohn's Disease with Autoimmune Overlap
The most likely unifying diagnosis is Crohn's disease (CD), with the constellation of markedly elevated anti-Saccharomyces cerevisiae antibodies (ASCA IgA and IgG), fecal calprotectin 500 µg/g, and fat-soluble vitamin deficiencies pointing directly to active inflammatory bowel disease with malabsorption. The high-titer ANA and thyroglobulin antibodies represent concurrent autoimmune thyroiditis, a well-documented association with CD 1.
Primary Diagnosis: Crohn's Disease
The serologic and inflammatory profile is highly specific for CD:
ASCA IgA and IgG double positivity identifies CD with 100% specificity 2. When both IgA and IgG are elevated together, this essentially confirms CD rather than ulcerative colitis or other inflammatory conditions.
Fecal calprotectin of 500 µg/g indicates active intestinal inflammation 3. This level (>150 µg/g threshold) strongly suggests endoscopic disease activity requiring evaluation and treatment adjustment.
Fat-soluble vitamin deficiencies (A, E, K) plus vitamin D deficiency indicate small bowel malabsorption, consistent with ileal or extensive CD involvement. This pattern reflects impaired absorption from inflamed intestinal mucosa.
Intermittent anti-gliadin antibody positivity likely represents cross-reactivity or secondary immune activation from intestinal inflammation rather than celiac disease, given the dominant ASCA pattern 4.
Concurrent Autoimmune Thyroiditis
The thyroglobulin antibody level of 1000 IU/mL with high-titer ANA (1:1280 speckled/homogeneous) indicates autoimmune thyroiditis (Hashimoto's thyroiditis). This is a recognized association with CD 1. Studies demonstrate that patients with autoimmune thyroid disease have elevated prevalence of antigliadin and other gut-related antibodies, suggesting shared autoimmune mechanisms.
Important caveat: The elevated thyroglobulin antibodies may contribute to malabsorption of thyroid hormone replacement if the patient is being treated, as latent CD can impair levothyroxine absorption 1.
Clinical Algorithm for Management
Immediate next steps:
Endoscopic evaluation (colonoscopy with ileoscopy) is mandatory given the elevated calprotectin >150 µg/g with symptoms 3. The AGA guidelines specifically recommend endoscopic assessment rather than empiric treatment when biomarkers are elevated.
Obtain biopsies from terminal ileum, right colon, and throughout the colon to confirm CD diagnosis histologically and assess disease extent.
Exclude enteric infections (particularly Clostridioides difficile) before attributing symptoms solely to CD, as calprotectin elevates with any gut inflammation 3.
Assess thyroid function (TSH, free T4) given the high thyroglobulin antibodies and evaluate for hypothyroidism requiring treatment.
Nutritional repletion: Replace vitamin D, A, E, and K deficiencies. Consider parenteral administration initially if severe malabsorption is confirmed.
Disease Severity and Prognosis
ASCA positivity (especially IgA) predicts more aggressive CD phenotype 5. Patients with elevated ASCA IgA have an 8.5-fold increased risk of requiring surgery within 3 years of diagnosis. This patient requires:
- Early aggressive therapy consideration (biologics rather than step-up approach)
- Close monitoring with repeat calprotectin every 2-4 months during active treatment 3
- Endoscopic reassessment 6-12 months after treatment initiation to confirm mucosal healing
Common Pitfalls to Avoid
Do not attribute all symptoms to thyroid disease alone. The combination of elevated calprotectin and ASCA double positivity cannot be explained by thyroiditis and demands GI evaluation.
Do not delay endoscopy. With calprotectin >150 µg/g, empiric treatment adjustment without endoscopic confirmation is inappropriate per AGA guidelines 3.
Do not misinterpret intermittent anti-gliadin positivity as celiac disease. The dominant ASCA pattern and absence of anti-tissue transglutaminase or anti-endomysial antibodies (not mentioned as positive) makes CD far more likely. Anti-gliadin antibodies have poor specificity and occur in various inflammatory conditions 4, 1.
Monitor for treatment response using calprotectin. Target normalization (<150 µg/g, ideally <50 µg/g) correlates with endoscopic remission 3.
The fatigue likely stems from multiple factors: active intestinal inflammation, vitamin D deficiency, potential hypothyroidism, and possible anemia from chronic disease or malabsorption. All require concurrent management alongside the primary CD treatment.